Beyond accuracy metrics: Toward responsible integration of large language models in pediatric diagnostic reasoning

A child who cycles through years of inconclusive workups before a rare disease diagnosis is finally made represents more than a statistical outlier; it is a failure of the diagnostic system itself.1 It is against this reality that Launes and colleagues evaluated four large language models (LLMs) head-to-head with 78 clinicians across 50 real cases, half common and half rare, drawn from electronic health records at a major tertiary children's hospital in Barcelona.2 What they found is striking: o1-preview and Claude-3.5 Sonnet outperformed the clinician cohort by a wide margin, and the gap was widest precisely where diagnostic difficulty is greatest, in rare disease recognition. These are not marginal differences on board-style questions; they emerged from authentic, messy, intake-level clinical data. The study raises hard questions about where LLMs belong in the diagnostic workflow, and this editorial considers what those findings mean in practice and where they fall short. The most clinically compelling finding is not that LLMs outperformed clinicians on aggregate metrics, but where that advantage was concentrated. The o1-preview model demonstrated 6-fold higher Top-5 diagnostic odds for rare diseases (odds ratio = 6.00, P < 0.001)—a domain where diagnostic latency averages 4–7 years and misdiagnosis rates remain alarmingly high.1, 3 This aligns with evidence that LLMs possess particular advantages in pattern recognition across vast differential landscapes, precisely the cognitive terrain where even experienced clinicians encounter anchoring bias and premature closure.4, 5 Equally noteworthy, clinical experience level did not correlate with diagnostic accuracy. Senior attendings, junior attendings, and residents performed comparably across the case set (Top-5 accuracy: 60.3%, 64.0%, and 65.5%, respectively; P = 0.608). This counterintuitive result resonates with prior literature demonstrating that non-prototypical, analytically demanding cases depend more on structured reasoning than on experiential pattern recognition.6 The implication is profound: if expertise confers no measurable advantage on already-compiled clinical data, then artificial intelligence (AI)-augmented differential generation may represent a genuine equalizer, particularly in resource-limited settings where subspecialty consultation is inaccessible.7 Several methodological features distinguish this study from prior LLM benchmarking efforts. First, the use of authentic intake-style clinical summaries derived from electronic health records rather than curated vignettes from medical journals substantially raises ecological validity. Published case challenges are often editorially refined for pedagogical clarity, inadvertently inflating LLM performance by presenting well-structured diagnostic cues.8, 9 The incomplete histories and multisystem presentations in this dataset better approximate undifferentiated first-line encounters. Second, the triplicate querying strategy with intraclass correlation coefficient (ICC) analysis addresses a critical but frequently overlooked dimension of LLM evaluation: output consistency. The finding that o1-preview exhibited the highest accuracy but the lowest response consistency introduces a clinically important tension. A model that is brilliant but unpredictable poses fundamentally different risks than one that is moderately accurate but reliably so.10 The joint performance profile, mapping accuracy against ICC, deserves adoption as a standard reporting framework, as it captures reliability in a way that single-point accuracy metrics cannot. Third, the human–AI complementarity analysis, yielding 94.3% union accuracy with o1-preview (a 10-percentage-point uplift over clinicians alone), provides empirical support for the augmentation hypothesis. Neither party held a consistent advantage, and their combined output exceeded either in isolation—a finding with direct implications for how diagnostic workflows should be designed.11 The rapid evolution of LLM diagnostic capabilities is evident when these results are situated alongside the broader literature. Earlier evaluations using GPT-3.5 on pediatric case challenges demonstrated an 83% error rate,8 yet fine-tuned models have since achieved performance comparable to board-certified pediatricians in community settings,7 and general-purpose frontier models now surpass clinicians on authentic clinical presentations.12 The present study—demonstrating that GPT-4 (0613) was the weakest performer while newer architectures excelled—underscores the hazards of drawing durable conclusions from evaluations of rapidly obsolescing model versions.4, 13 However, the 60% Top-1 accuracy ceiling means that in four of ten cases, the most likely LLM-generated diagnosis was incorrect. In a domain where missed diagnoses carry irreversible consequences—particularly in pediatric oncology, metabolic emergencies, and non-accidental trauma—this error rate demands interpretive caution. Furthermore, studies evaluating LLMs on ultra-rare genetic diseases (prevalence < 1:100 000) have reported Top-1 accuracies of only 8%–13%,14 suggesting that the moderate-rarity range (1:10 000–1:100 000) represented in this study may represent a performance sweet spot rather than a generalizable benchmark. The single-center tertiary design may overrepresent diagnostically complex cases while underrepresenting routine primary care presentations.15 Volunteer bias among clinicians who self-selected for a “clinical case marathon” may have yielded a human benchmark not representative of typical clinical performance. The Castilian Spanish presentation format introduces an additional confound, as LLM performance across languages and dialects is known to be heterogeneous,16 and whether these results generalize to other documentation systems remains uncertain. Additionally, the evaluation bypasses the iterative nature of real diagnostic reasoning, history-taking, examination, and test ordering, and the “union accuracy” metric assumes clinicians would accept correct AI-proposed diagnoses, an assumption that behavioral evidence on automation bias suggests may be optimistic.17 First, prospective randomized controlled trials assessing whether LLM-augmented clinicians achieve superior diagnostic outcomes are essential. The recent demonstration that GPT-4 assistance improved physician performance in a randomized trial represents an important precedent,11 but pediatric-specific replication with attention to rare disease endpoints is needed. Second, the consistency problem demands architectural solutions. Temperature calibration, ensemble methods, and confidence-stratified interfaces may help clinicians interpret LLM suggestions appropriately.10 The observation that Claude-3.5 Sonnet achieved both high accuracy and high consistency demonstrates these properties are not inherently antithetical, and that model selection should prioritize reliability alongside raw performance. Third, regulatory frameworks must evolve commensurately with the technology. The European Union AI Act's classification of medical diagnostic systems as high-risk applications is a necessary starting point, but transformer-based architectures challenge traditional conformity assessments.18, 19 A phased integration approach—initially restricting LLMs to advisory roles with mandatory verification and outcome tracking—would generate the real-world evidence needed to refine both algorithms and governance structures. Fourth, educational curricula must prepare clinicians not merely to use AI tools, but to interrogate them. The finding that extended clinical information substantially improved both human and LLM accuracy reinforces the irreplaceable value of thorough clinical data acquisition—a skill honed through practice, not algorithms.6, 20 Clinicians must learn to distinguish clinically coherent from superficially plausible outputs, and to understand that a model's confident tone does not correlate with its probabilistic calibration. What Launes et al.2 have given us is not a finished answer but a well-constructed proof of concept, and an honest one, complete with the consistency problems and accuracy ceilings that temper enthusiasm. The data make a strong case that LLMs belong somewhere in the pediatric diagnostic workflow, particularly when rare diseases are on the table. But belonging somewhere is not the same as belonging everywhere, and a 60% Top-1 hit rate, however impressive relative to clinicians, still means getting it wrong first more often than getting it right. The real work ahead is not technical alone; it is organizational, educational, and regulatory. Trials that test whether these tools actually change outcomes when a clinician is in the loop, not just whether they can generate a correct differential from a pre-compiled summary, are the necessary next step. And the next generation of pediatricians must be trained as discerning consumers of AI output, skeptical enough to catch errors, but open enough to let the technology expand their diagnostic reach to the children who need it most. The author declares no conflict of interest.